The need for a personalized approach for prostate cancer management by JP Michiel Sedelaar & Jack A Schalken
Sedelaar and Schalken BMC Medicine  (2015) 13:109 
DOI 10.1186/s12916-015-0344-1COMMENTARY Open AccessThe need for a personalized approach for
prostate cancer management
JP Michiel Sedelaar* and Jack A SchalkenAbstract
The stratification of patients for treatment of prostate cancer is based on very general parameters like prostate-specific
antigen, Gleason score, and TNM classification. We use these rough parameters for selection of active surveillance, active
treatment, and even for the treatment selection in metastasized or castration-resistant prostate cancers. Up to now, we
have not used individualized genetic classifiers for detailed sub-stratification, thus treating all patients as equal, and being
only moderately successful. With the expected increase in systemic treatments, there is an apparent need for such
classifiers. We will address these needs in this short commentary.
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In current urology practice, most men diagnosed with
prostate cancer will present with local or locally ad-
vanced disease. They will be candidates for curative
treatment with either radical surgery or radiation ther-
apy. Despite this shift towards diagnosis at a more favor-
able clinical stage of prostate cancer, between 20% and
30% of these patients will have a biochemical relapse
and need additional therapy [1]. At that point, most
patients will first receive some form of salvage therapy,
although a considerable number of patients will eventu-
ally need androgen deprivation therapy to treat metasta-
sized prostate cancer. Androgen deprivation therapy is
not a curative option in the treatment of prostate cancer,
leading to castration-resistant prostate cancer and even-
tually death from prostate cancer in most cases.
The description of this clinical history is not uncom-
mon, and underlines the limitations we encounter in
determining the prognosis of individuals with prostate
cancer. There is a clear, unmet need for reliable and
reproducible prognostic biomarkers that can stratify
patients on prognosis and identify who could benefit from
early adjuvant treatment instead of salvage treatment.
Current diagnostic and prognostic tools
The current diagnostic tools we mostly use are serum
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histopathological Gleason grading. Of these diagnostic
tools, only PSA can be classified as a biomarker and has
limited performance status [2]. Because of these limita-
tions in predicting prognosis, the treatment dilemma
can lead to over-treatment, as well as under-treatment.
Treating all patients in the adjuvant setting will lead to a
considerable percentage of unnecessary complications
and side effects (over-treatment), whereas treating pa-
tients only in a salvage setting will lead to relative late
treatments and chance for failure of this treatment
(under-treatment).
Research efforts have been undertaken to improve the
prognostic stratification of the individual patient. Several
markers complementary to PSA have been introduced
and investigated. Most notable are the prostate health
index, the OPKO 4K score, and PCA3 [3,4]. Although
all of these biomarkers are promising in predicting
biopsy outcome, none of these tests has been able to
adequately predict the biological potential of the cancer
in individual patients. Combining one or several of these
biomarkers with state-of-the-art imaging modalities like
multiparametric magnetic resonance imaging or PSMA-
positron emission tomography combined with computed
tomography could be considered as a step in the right
direction.
Hence, there is an urgent need for reproducible prog-
nostic biomarkers as an adjunct to histopathological
grading. Gleason grading is still one of the more robustd Central. This is an Open Access article distributed under the terms of the
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decision-making despite high intra- and inter-observer
variability. Additionally, there have been significant
changes in evaluation criteria, especially in the most fre-
quent Gleason 3 and 4 patterns from which most treat-
ment dilemmas (‘to treat or not to treat’) arise.
Molecular prognostic tools
Genomic and molecular classifiers could greatly help
with these previously mentioned clinical dilemmas. The
best-evaluated example of such a molecular classifier is
the Oncotype DX in the field of breast cancer. Oncotype
DX (Genomic Health, Inc., Redwood City, CA, USA) is a
tissue-based gene expression-profiling test that was first
marketed in the US in 2004. It was designed to measure
the 10-year risk of tumor recurrence in early-stage
breast cancer at the time of initial diagnosis. Risk is
reported as a 21-gene signature or recurrence score
on a scale of 0 to 100. It is widely used in the US al-
though the clinical benefits are still not completely
understood [5].
For prostate cancer, two new molecular classifiers are
now available for aiding decision-making for either ac-
tive surveillance or intervention: Prolaris (cell cycle pro-
gression score) [6] and the Oncotype DX Genomic
Prostate Score [7]. Both tests have been introduced
for clinical decision-making for patients with low- orFigure 1 Schematic presentation of the classic steps in the early diagnosis
Food and Drug Administration-approved tests or those offered by CLIA lab
MRI, magnetic resonance imaging; PCA3, prostate cancer gene 3; PHI, Prosintermediate-risk prostate cancer who can choose be-
tween active surveillance or intervention. The tests
are available as laboratory-developed tests by Clinical
Laboratory Improvement Amendments laboratories.
However, the treatment dilemma for patients with
intermediate- or high-risk prostate cancer (that is,
whether to give adjuvant (radio) therapy) has not yet
been thoroughly addressed for the above-mentioned
genomic test.
In their recently published article, Den et al. [8] de-
scribe the use of a validated 22-marker prostate cancer
genomic classifier (Decipher) to identify patients with
intermediate- or high-risk prostate cancer who could
benefit from early adjuvant radiotherapy, compared to
salvage treatment radiotherapy, after initial radical sur-
gery. The 22-marker panel genomic classifier (GC) has
been validated in previous studies and is performed on
patient tissue specimens. For all patients, the Cancer of
the Prostate Risk Assessment Post-Surgical (CAPRA-S)
score was determined as was the Stephenson 5-year
nomogram survival probability in addition to the GC
score. In comparison with both the CAPRA-S and the
Stephenson nomogram, the GC was the most prominent
predictor of metastasis using a variety of statistical prob-
ability tests. A reclassification analysis showed that 71
patients (43%) with average- or high-risk CAPRA-S
scores had their risk downgraded to GC low risk, and 69of prostate cancer and the same approach implementing recent US
oratories. CCCP, cell cycle control panel; GPS, Genomic Prostate Score;
tate Health Index; PSA, prostate-specific antigen.
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study follow-up. No information is given about possible
biochemical recurrence in these patients. These findings
illustrate the utility of an individualized and tailored
approach in the management of intermediate- and high-
risk post-prostatectomy patients with adverse histo-
pathological findings.
There are some limitations in the presented study. In
this retrospective study the decision for adjuvant radio-
therapy was variable and differed among clinicians, while
the decision for salvage radiotherapy was more guideline
based. With this subjective selection it is impossible to
conclude that the timing of early adjuvant treatment
based on a genomic classifier is the main reason for
the improved outcome. Also the use of androgen
deprivation therapy adjuvant to the prostatectomy in
some patients was non-guideline based. The ‘adjuvant’
use of hormonal treatment could have influenced the
downgrading of the stage, serving as a stage migration,
while not influencing the genomics. This could again ex-
plain the positive outcomes for the GC group receiving
adjuvant treatment. In a prospective setting, with strict
criteria for additional hormonal treatment and guidelines
for when to proceed with adjuvant treatment, the con-
clusions would be more robust. Lastly, in this study
there was no control group without radiotherapy adju-
vant to radical prostatectomy. Without this control
group no conclusions can be made on the benefit of the
‘additional’ radiotherapy compared to no radiotherapy.
Conclusions
Den et al. [8] presented an interesting new personal-
ized approach for intermediate- and high-risk patients
for whom adjuvant or salvage radiotherapy post-
prostatectomy is indicated. Using a GC, these patients
can be guided towards a personalized treatment ap-
proach, as illustrated in Figure 1. In the future, these
findings must be confirmed in prospective trials. An-
other more compelling future study design could be
the use of the GC-Decipher test as an add-on in systemic
treatment studies for pre- and post-chemotherapy inter-
ventions. Identifying patients who can benefit the most
from new systemic treatments could greatly improve the
chances for survival for selected patients with castration-
resistant prostate cancer.
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